242 related articles for article (PubMed ID: 19476859)
21. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
22. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
23. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
25. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.
Glaser RL; York AE; Dimitrakakis C
Menopause; 2017 Jul; 24(7):859-864. PubMed ID: 28195993
[TBL] [Abstract][Full Text] [Related]
27. Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.
McGuire KP; Hwang ES; Cantor A; Golshan M; Meric-Bernstam F; Horton JK; Nanda R; Amos KD; Forero A; Hudis CA; Meszoely I; De Los Santos JF
Ann Surg Oncol; 2015 Jan; 22(1):75-81. PubMed ID: 25059792
[TBL] [Abstract][Full Text] [Related]
28. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Skriver SK; Jensen MB; Knoop AS; Ejlertsen B; Laenkholm AV
Breast Cancer Res; 2020 May; 22(1):46. PubMed ID: 32410705
[TBL] [Abstract][Full Text] [Related]
29. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
30. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
Jochelson MS; Lampen-Sachar K; Gibbons G; Dang C; Lake D; Morris EA; Morrow M
Ann Surg Oncol; 2015 May; 22(5):1490-5. PubMed ID: 25777093
[TBL] [Abstract][Full Text] [Related]
31. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Neoadjuvant Chemotherapy on Margin Re-excision in Breast-Conserving Surgery.
Devane LA; Baban CK; O'Doherty A; Quinn C; McDermott EW; Prichard RS
World J Surg; 2020 May; 44(5):1547-1551. PubMed ID: 32002582
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
34. Rationale for Mastectomy after Neoadjuvant Chemotherapy.
Gusic LH; Walsh K; Flippo-Morton T; Sarantou T; Boselli D; White RL
Am Surg; 2018 Jan; 84(1):126-132. PubMed ID: 29428039
[TBL] [Abstract][Full Text] [Related]
35. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; van den Bosch J; Maartense E; van Leeuwen-Stok AE; Liefers GJ; Nortier JWR; Rutgers EJT; van de Velde CJH;
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922787
[TBL] [Abstract][Full Text] [Related]
36. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
[TBL] [Abstract][Full Text] [Related]
37. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
[TBL] [Abstract][Full Text] [Related]
38. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Mamounas EP
Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
[TBL] [Abstract][Full Text] [Related]
39. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Allevi G; Strina C; Andreis D; Zanoni V; Bazzola L; Bonardi S; Foroni C; Milani M; Cappelletti MR; Gussago F; Aguggini S; Giardini R; Martinotti M; Fox SB; Harris AL; Bottini A; Berruti A; Generali D
Br J Cancer; 2013 Apr; 108(8):1587-92. PubMed ID: 23579222
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
